Discover our biggest data expansion to date with DISGENET v25.1—your platform for deeper, more actionable disease-genomics insights to accelerate research and advance precision medicine.
DISGENET version 25.1 includes:
- Expanded Data Sources for In-Depth Research
- Integrated GWAS Data for Targeted Filtering
- Personalized Ancestry-Specific Insights
- Enhanced Biomarker Discovery with Improved NLP
- Improved Chemical Searches & Pharmacogenomic Discovery
A Data Revolution to Power Your Discoveries
In our latest release, we’re not just expanding the breadth of our data—we’re enhancing its depth to empower your research with unprecedented detail.
DISGENET v25.1 introduces a comprehensive update to our data sources, providing you with the most robust, up-to-date evidence available for target identification, drug safety assessments, and biomarker discovery.
Key data increases include:
- Variants: Up by 96% (over 1.4 million)
- Chemicals & Drugs: Up by 262% (over 14,000)
- Variant-Disease Associations (VDAs): Up by 253% (over 4.3 million)
This significant expansion helps you cut through data silos and offers a richer, more reliable dataset, enabling you to base your research decisions on a solid foundation of high-quality evidence.
Clarity in the Complexity
Advanced GWAS Integration & Filtering
For drug R&D teams and clinical labs, faster, more targeted research is now possible. DISGENET v25.1 integrates advanced Genome-Wide Association Study (GWAS) data from both the UK Biobank and FinnGen.
Our new biobank filters allow you to:
- Isolate large-scale GWAS data by choosing UK Biobank, FinnGen, or both to focus on population-scale insights.
- Contextualize your findings by easily comparing biobank-sourced data with curated datasets and the latest scientific literature, helping you quickly focus on the most relevant associations for your research.
These improvements enable faster, more targeted research, ensuring you can focus on what truly matters.
Precision Medicine in Action
Ancestry-Specific Insights
Precision medicine relies on understanding the genetic diversity that defines patient populations. With DISGENET v25.1, you can now access enhanced ancestry-specific insights that are critical for developing targeted therapies.
For Web Platform Users:
- Gain deeper insights into genetic variation across diverse populations with detailed GWAS summary statistics—now including ancestry data.
- Achieve clearer, more actionable insights for biomarker or target validation with refined metrics—Odds Ratio and Beta coefficients are now separated into distinct columns in the VDA evidence table.
- Ensure more accurate findings across a wide range of populations with the inclusion of published ancestry data, reflecting real-world genetic diversity in your analysis.
For REST API Users:
- Optimize your research for better clinical outcomes by targeting specific populations through advanced ancestry filtering—filter variant-disease associations by ancestry using standard identifiers from the Hancestro ontology.
By integrating these advanced tools into your workflow, you can accelerate your journey toward precision medicine that is truly personalized.
Faster, More Reliable Biomarker Discovery
Improved NLP Pipeline for Clinical Trials
In drug discovery and clinical diagnostics, speed and accuracy are critical. In v25.1, we’ve enhanced our Natural Language Processing (NLP) pipeline for clinical trials to improve the capture and summarization of biomarker evidence.
Now, a quick glance at the GDA evidence table’s Sentence column provides a concise text snippet that highlights key biomarker insights—-helping you to accelerate target validation and improve diagnostic precision.
More Flexible Chemical Searches
Discover Pharmacogenomic Associations
Navigating complex chemical data is now simpler. Our improved search capabilities support multiple identifiers—including ChEMBL, PubChem, DrugBank, and ChEBI—across GDA, VDA, and Chemical endpoints in our REST API.
This allows you to:
- Easily identify drugs associated with gene-disease associations (GDAs) and variant-disease associations (VDAs).
- Pinpoint potential pharmacogenomic interactions, offering new avenues for drug repurposing and biomarker discovery, thanks to the improved recognition of chemicals and drugs.
Your Roadmap to Future Innovations
DISGENET v25.1 combines rigorous technical enhancements with actionable research benefits to help you reduce R&D costs, accelerate target validation, and drive breakthrough discoveries.
Whether you’re advancing drug discovery in biotech and pharma or refining diagnostics in clinical genomics, our latest release equips you with the data and tools needed to stay ahead.